GENE ONLINE|News &
Opinion
Blog

2022-03-03| China

Sanofi Bets $2.5 billion on Adagene to Make Antibodies Safer

by Joy Lin
Share To

Sanofi is betting more than $2.5 billion on Adagene’s masking technology to make antibodies safer. The Suzhou, China-based biopharma has agreed to conduct early stage research to develop up to four antibody candidates selected by Sanofi.

The French drug giant will pay Adagene $17.5 million upfront to collaborate on two initial candidates, while Sanofi can choose to add two more. The candidates will be exclusively developed in later stages and commercialized by Sanofi. Adagene could receive up to $2.5 billion if milestones for all four programs are achieved, as well as royalties on product sales. 

Related Article: Chinese Oncology Drugmaker to Raise over $600 Million in Hong Kong IPO

 

Making Activatable Antibodies 

 

Adagene’s masking platform, which it calls SAFEbody, aims to address safety and tolerability issues faced by many immunotherapies. 

SAFEbody uses a masking peptide to shield the binding domain of the antibody, similar to putting a cap on a pen to prevent ink from leaking inside the bag. 

The masked antibody only activates in the tumor-microenvironment, allowing the drug to target cancer cells with more specificity while minimizing off-target toxicity to healthy tissue. 

Adagene claims that its masking technology can be applied to other immunotherapies such as bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell engagers (TCEs).

 

Adagene’s SAFEbody Collabs

 

Other companies have seen potential in Adagene’s masking platform. 

Last February, Exelixis signed a pact with Adagene to generate masked monoclonal antibodies to be further developed into ADCs. The deal included an $11 million upfront payment to Adagene as well as $780 million in milestones. 

And even earlier, Adagene penned an agreement with Tanabe Research Laboratories to develop an ADC against a solid tumor target. Adagene has also licensed its SAFEbody technology to ADC Therapeutics in a deal worth $166 million to develop an ADC against cancer. 

Related ArticleSanofi Bets $1 Billion on Preclinical Next-gen Immunotherapies

 

Sanofi’s Appetite for Next-Gen Immuno-oncology

 

Meanwhile, Sanofi has shown its desire to be at the forefront of immuno-oncology. After Takeda snapped up masking technology developed by biotechs such as Maverick, Sanofi announced a deal to acquire Amunix for over $1 billion. The buyout gave Sanofi a masking platform for developing TCEs and cytokine therapies, as well as Amunix’s lead candidate, a masked HER2-directed TCE.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Gilead Spends $405 Million In Cash to Acquire MiroBio
2022-08-05
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!